Group B streptococcus (GBS) is a leading cause of neonatal morbidity and mortality in the United States. In 2002, CDC, the American College of Obstetricians and Gynecologists (ACOG), and the American Academy of Pediatrics (AAP) issued revised guidelines for the prevention of perinatal GBS disease. These guidelines recommend universal screening of pregnant women by culture for rectovaginal GBS colonization at 35-37 weeks' gestation and the use of intrapartum antibiotic prophylaxis for GBS carriers (1) . To examine rates of neonatal and pregnancyassociated GBS disease after the revised guidelines were issued, CDC analyzed surveillance data from the Active Bacterial Core surveillance (ABCs) system from the period 2003-2005 and compared them with data from 2000-2001, the period immediately preceding the universal screening recommendations. This report describes the results of that analysis, which indicated that annual incidence of early onset GBS disease (i.e., in infants aged 0-6 days) was 33% lower during 2003-2005 than during 2000-2001. However, although incidence among white infants decreased steadily during [2003] [2004] [2005] , incidence increased 70% among black infants. Incidence of GBS disease among infants aged 7-89 days (i.e., late-onset disease) and pregnant women remained stable after revised universal screening guidelines were issued. Continued surveillance is needed to monitor the impact of the guidelines on perinatal GBS disease and trends in racial disparities and to guide interventions to reduce disparities.
ABCs, part of CDC's Emerging Infections Program (EIP) network, conducts active, laboratory-and population-based surveillance in selected counties of 10 states for invasive GBS disease,* defined as isolation of GBS from a normally sterile site or from the placenta or amniotic fluid in cases of fetal death. In 2004, the surveillance area represented approximately 455,000 live births; 72% of the infants were white, 19% were black, and 9% were of other race. Surveillance areas used standardized case-report forms to collect demographic, neonatal, and obstetric data from medical records. Race and ethnicity were determined from medical records or birth certificates. Multiple imputations were used to account for missing race data (2) . Live-birth data from state vital records and national vital statistics reports were used as denominators for incidence calculations. A total of 167 EOD cases were reported for 2005, the year when racial disparities were largest. Incidence of EOD in 2005 was 0.37 cases per 1,000 live births and varied by surveillance area (Table) . By race, 44% were white, 39% were black, 4% were of other race, and 12% were of unknown race. Of GBS isolates from EOD cases, 97.6% were from blood only, 1.8% were from blood and cerebrospinal fluid (CSF), and 0.6% were from CSF only. The case-fatality ratio was 5%. Among EOD cases for which gestational age data were available (164 of 167), 29% occurred in infants born preterm (i.e., at <37 weeks' gestation). Among black infants with EOD, 40% of cases occurred in infants born preterm, compared with 24% of as a leading cause of neonatal sepsis (6) . Factors that might contribute to this disparity include higher maternal colonization rates in blacks (7), higher rates of preterm deliveries (a risk factor for neonatal GBS disease) among blacks, and less access to prenatal care among black women compared with white women. However, a study that controlled for these factors indicated that black race remained an independent risk factor for disease (8) . Healthy People 2010 objectives include achieving rates of EOD below 0.5 cases per 1,000 live births for all racial populations. Rates of EOD among white infants reached this target in 1998 and have remained below this level since the universal screening recommendations were issued. In 2003, the year after the recommendations were issued, incidence among black infants reached a record low (0.52 per 1,000 live births) and suggested that national health objectives might also be met for black infants (9; CDC, unpublished data, 2007). However, during the following 2 years, incidence of EOD among black infants returned to levels observed before the recommendations were issued. Continued surveillance is needed to determine whether this trend persists and to identify possible barriers to universal screening for pregnant black women. The findings in this report are subject to at least two limitations. First, although the surveillance system describes trends in disease, these results alone are not sufficient to determine causes of increases or decreases in GBS disease rates. Second, these results alone do not measure healthcare-provider compliance with the guidelines; therefore, changes in incidence of GBS cannot be attributed directly to compliance with prevention guidelines. Although increases in rates of EOD among black infants were reported, whether these increases are attributed to barriers in implementation of the guidelines is not known. To overcome these two limitations, CDC is collaborating with the EIP network to conduct Birthnet, a review of maternal labor and delivery records of live births in 10 ABCs states during [2003] [2004] . The purpose of the study is to characterize provider compliance to universal screening guidelines, identify barriers to implementation, detect missed prevention opportunities, and increase understanding of racial disparities.
Universal screening and IAP are the most effective measures available for EOD prevention. Rates of EOD were lower after the universal screening recommendations were issued, compared with the baseline period. However, even optimal implementation of the recommendations is unlikely to eliminate EOD because neither screening for GBS carriers nor IAP is 100% effective. When the guidelines were issued, the potential impact of screening and IAP on LOD was unknown; the exact modes of transmission for LOD were not well understood, and vertical transmission might have only a limited role. This report indicates minimal change in rates of LOD and infections in pregnancy since the universal screening recommendations were issued.
The use of a GBS vaccine could be effective in preventing perinatal GBS disease, possibly also preventing stillbirths and premature deliveries attributed to GBS. Vaccination might also help reduce racial disparities in disease. Several potential vaccines are under consideration, some of which have completed Phase II trials (10) .
Information for patients, health-care providers, and public health practitioners regarding GBS is available from CDC at http://www.cdc.gov/groupbstrep. Brochures are available in both English and Spanish by telephone (404-639-2215); information regarding bulk orders is available through the CDC Foundation by telephone (877-252-1200). Secondhand smoke (SHS) causes premature disease and death in nonsmokers, including heart disease and lung cancer (1) . The Surgeon General has concluded that no risk-free level of SHS exposure exists; the only way to fully protect nonsmokers is to completely eliminate smoking in indoor spaces (1) . Studies have determined that levels of airborne particulate matter in restaurants, bars, and other hospitality venues and levels of SHS exposure among nonsmoking hospitality employees decrease substantially and rapidly after implementation of laws that prohibit smoking in indoor workplaces and public places (1) (2) (3) (4) (5) . To assess changes in indoor SHS exposure in a general population, the New York State Department of Health analyzed data on observations of indoor smoking by respondents to the New York Adult Tobacco Survey (NYATS) and measured levels of cotinine* in saliva among nonsmoking NYATS respondents before and after implementation of the 2003 New York state ban on smoking in indoor workplaces and public places. This report describes the results of that analysis, which determined that reports of indoor smoking among restaurant and bar patrons decreased significantly after the law took effect; moreover, saliva cotinine levels in nonsmoking NYATS participants decreased by 47.4% over the same period. These findings suggest that comprehensive smoking bans can reduce SHS exposure among nonsmokers.
NYATS is an ongoing, quarterly, random-digit-dialed telephone survey of approximately 2,000 state residents aged >18 years designed to generate state and regional estimates of tobacco-use behaviors and related attitudes and beliefs among adults living in residential households. Initial NYATS data collection began on June 26, 2003, less than 1 month before implementation of the statewide law on July 24, 2003.
To assess levels of indoor smoking in restaurants, bars, and workplaces, all NYATS participants were asked three questions: "The last time you went to a restaurant in your community in the past 30 days, did you see someone smoking indoors?" "The last time you went to a bar in your community in the past 30 days, did you see someone smoking indoors?" and "In the past 7 days, has anyone smoked in your work area?" To assess smoking status, NYATS participants were asked, "Do you now smoke cigarettes every day, some days, or not at all?" Nonsmokers were defined as those who answered "not at all."
All nonsmokers who participated in NYATS during June 26, 2003-June 30, 2004, and who lived outside New York City and Nassau County were eligible to participate in a saliva cotinine study and were invited to submit a saliva sample through the mail for cotinine analysis. Saliva cotinine has been determined to be an accurate and reliable measure of SHS exposure (1), and saliva cotinine samples remain stable when submitted by mail (6) . Residents of New York City and Nassau County were excluded because those jurisdictions had implemented comprehensive local smoking bans in March 2003; as a result, their residents might have already experienced declines in SHS exposure. Participants who agreed to provide a saliva sample were mailed a packet that included a consent form, a vial, instructions for providing the sample, a $10 incentive check, and a postage-paid return mailer. Eligible NYATS participants who did not submit a sample within 2 weeks were mailed postcard reminders. The 296 respondents whose samples were too small for analysis were not asked to provide an additional sample. The 96 respondents whose samples yielded cotinine values >15 ng/mL were excluded from the analysis because those values are associated with active smoking (1) .
The concentration of cotinine in the saliva samples was determined using liquid chromatography with tandem mass spectrometry. This method has a limit of detection (LOD) of 0.05 ng/mL. For participants with a cotinine level below the LOD, values were imputed by applying an expectation-maximization regression model to the logtransformed cotinine levels that were above the LOD (7). This method generates estimates of values below the LOD to replicate the true distribution of the sample (i.e., the distribution that would have been observed had there been no LOD). The method is recommended when the proportion of samples with values below the LOD exceeds 40% to provide the best estimate of the true shape of the distribution while avoiding distortions that result from assigning a single value to samples with cotinine levels below the LOD (7, 8) .
Response rates for NYATS, calculated according to the Council of American Survey Research Organizations for- Response rates for the cotinine study, calculated as the number of participants submitting saliva samples divided by the number of eligible participants, averaged 33% (range: 27%-41%). NYATS data regarding both reported indoor smoking and cotinine levels were weighted to account for nonresponse, demographics, and geographic location. Participants in the cotinine study were similar to all nonsmoking NYATS participants in terms of age group, education level, race/ethnicity, and self-reported health status, with two exceptions. A greater proportion of participants in the cotinine study had college degrees and were non-Hispanic white than the nonsmoking NYATS participant population overall ( Table 1) .
Reports of Indoor Smoking
The percentages of NYATS respondents reporting exposure to SHS in restaurants and bars decreased significantly after the law took effect, from 19.8% (during June 26-July 23, 2003) to 3.1% (during April 1-June 30, 2004) among restaurant patrons and from 52.4% to 13.4% among bar patrons over the same period ( Table 2 ). The percentage of respondents reporting exposure to SHS in workplaces, which had been 13.6% before implementation of the smoking ban, did not change significantly after implementation of the law. This finding likely is attributable to local smokefree air laws and voluntary workplace smoking restrictions that were in place before implementation of the state law.
Nonsmoker Levels of Cotinine
Of the 6,152 NYATS participants who were eligible to submit saliva samples, 3,053 agreed, and 2,008 (33%) submitted samples. The analysis described in this report is based on the 1,594 saliva samples that contained sufficient saliva to test for cotinine, had a cotinine level of <15 ng/mL, and were accompanied by a signed consent form. Saliva samples were analyzed at the New York Department of Health Wadsworth Laboratory.
The geometric mean level of salivary cotinine among nonsmoking NYATS participants who submitted saliva samples decreased by 47.4%, from 0.078 ng/mL during June 26-July 23, 2003, before the state law took effect, to 0.041 ng/mL during April 1-June 30, 2004 ( Table 3 ). The proportion of respondents with cotinine levels below the LOD (0.05 ng/mL) increased from 32.5% to 52.4% when comparing the same periods.
Editorial Note: Revised Healthy People 2010 objectives call for reducing the proportion of nonsmokers aged >4 years who are exposed to SHS to 63% (objective 27-10), increasing the proportion of indoor workers covered by smokefree air workplace policies to 100% (objective 27-12), and implementing laws making indoor workplaces and public places smoke-free in all 50 states (objective 27-13). The proportion of the U.S. population exposed to SHS has decreased substantially during the past 20 years as the prevalence and strength of local and state smoke-free air laws and voluntary workplace smoking restrictions have increased and adult smoking prevalence has decreased (1,9,10). However, approximately 126 million nonsmokers in the United States remain exposed to SHS (1) .
Studies have determined that laws prohibiting smoking in hospitality venues such as restaurants and bars are associated with rapid reductions in self-reported respiratory and sensory symptoms and improvements in objective measures of pulmonary function among nonsmoking hospitality workers (1, (3) (4) (5) . However, this is the first report of a biologically validated population-level reduction in SHS exposure among nonsmokers after implementation of a com- prehensive state smoke-free air law. The substantial reduction in saliva cotinine levels observed in this study likely indicates a substantial reduction in SHS exposure, which should result in reductions in morbidity and mortality from heart disease and lung cancer among nonsmoking adults over time (1) . The findings in this report are subject to at least two limitations. First, the average quarterly response rates for both NYATS (22%) and the saliva cotinine study (33%, for a cumulative rate of 7%) were low; in addition, the number of preban respondents in the cotinine study (80) was approximately one fourth to one fifth the number of respondents in each of the postban samples (range: 337-425). Although respondents in NYATS and the cotinine study might not be representative of the state's general populations of adults and adult nonsmokers, respectively, 2004 NYATS participants were similar to respondents in the 2004 New York state Behavioral Risk Factor Surveillance System survey in age group, education level, race/ethnicity, and self-reported health status. Moreover, an examination of age * Determined by answers to the following questions: "In the past 7 days, has anyone smoked in your work area?" "The last time you went to a restaurant in your community in the past 30 days, did you see someone smoking indoors?" "The last time you went to a bar in your community in the past 30 days, did you see someone smoking indoors?" Respondents who answered "yes" were considered to have reported seeing someone smoking in the specific venue. † Data were weighted to adjust for probability of selection, for nonresponse, and to match the most recent census projections for New York state reported by the U.S. Census Bureau. § t test for trend; p<0.001. ¶ Confidence interval. ** Sample sizes before the smoking ban were smaller because less time (<1 month) was available for data collection during that survey period than during the periods after the smoking ban went into effect. * Determined by the answer to the following question: "Do you now smoke cigarettes every day, some days, or not at all?" Respondents who answered "not at all" were considered nonsmokers. Respondents with cotinine levels >15 ng/mL (consistent with active smoking) were excluded from the analysis. † Data were weighted to adjust for probability of selection, for nonresponse, and to match the most recent census projections for New York state reported by the U.S. Census Bureau. § Confidence interval. ¶ Sample size before the smoking ban was smaller because less time (<1 month) was available for data collection during that survey period than during the periods after the smoking ban went into effect. ** Statistically significant difference in geometric means, indicated by nonoverlapping confidence intervals.
group, education level, and race/ethnicity demonstrated that cotinine study participants were similar to all nonsmoking NYATS participants, with two exceptions. Neither of these differences should negate the findings described in this report, although the low response rates do increase the possibility for error resulting from response bias. Second, a substantial proportion of respondent cotinine levels were below the LOD, and this proportion increased over time (likely because of the protection from SHS afforded by the new law). This required estimation of the values below the LOD to calculate the geometric means; although validated, this estimation is subject to error.
Additional research is needed to confirm the findings of this study. However, the results suggest that comprehensive smoke-free air laws can substantially reduce SHS exposure to nonsmokers, even in jurisdictions with a high prevalence of existing smoking restrictions. Even greater reductions in SHS exposure might be expected in jurisdictions that had fewer smoking restrictions in place before implementing a statewide smoke-free air law.
Smoking-Cessation Advice from Health-Care ProvidersCanada, 2005
Tobacco use is the most preventable cause of premature death and disease in Canada. In 2002, an estimated 37,209 Canadians died from illnesses related to tobacco use, accounting for 16.6% of all deaths in Canada (1). One of the objectives of the Canadian Federal Tobacco Control Strategy (FTCS) 2001-2011 is to reduce smoking prevalence in Canada from 25% to 20%. Although evidence indicates that an effective and efficient way of providing smoking-cessation information to smokers is through contact with health-care providers (2, 3) , little data in Canada exist regarding smokingcessation advice from this group. In 2005, the Canadian Tobacco Use Monitoring Survey (CTUMS) included questions to assess self-reported provision of cessation advice by health-care providers. This report summarizes the results of that survey, which indicate that only half of persons who visited health-care providers in the preceding 12 months received smoking-cessation advice, suggesting that healthcare providers need to take greater advantage of opportunities to provide such advice to smokers.
CTUMS was developed to provide Canada's federal health department (Health Canada) and its partners with timely, reliable data on tobacco use and related topics. The 2005 CTUMS collected data from approximately 20,800 respondents during February-December 2005. The target population was residents of all provinces of Canada aged >15 years; residents of the three territories (Yukon, Northwest Territories, and Nunavut) were excluded because of poor telephone coverage, as were institutionalized persons. The sample design was a two-phase stratified random sample of telephone numbers. In the first phase, households were selected using a random-digit-dialing method. In the second phase, one or two persons (or none) from the household were selected according to household composition. Data were collected using computer-assisted telephone interviewing, which ensured that only valid responses were entered and that all the correct procedures were followed. Data were weighted to provide national estimates.
CTUMS respondents who identified themselves as current smokers* were asked about their visits to various types of health-care providers, including physicians, dentists or dental hygienists, and pharmacists, in the 12 months before the survey. † For each health-care provider visited in the preceding 12 months, respondents were asked whether they were advised by the provider to reduce or quit smoking. § Those who said they had received advice were then asked whether they received any information on smokingcessation aids such as nicotine patches, a product such as Zyban ® , or counseling programs. ¶ According to the 2005 CTUMS, approximately 5 million residents in Canada (weighted data), representing 19% of the population aged >15 years, were current smokers, of whom 88% reported visiting one or more of the specified health-care providers (physician, dentist or dental hygienist, and pharmacist) in the 12 months before the survey (Table 1) . A greater proportion of female smokers (94%) visited a health-care provider in the preceding 12 months than male smokers (83%). Among female smokers, the highest rate of visiting a health-care provider was among respondents aged 25-34 years (97%), and the lowest was among those aged 15-19 years (91%). In contrast, among male smokers, the highest rate of visiting a health-care provider was among respondents aged 15-19 years (87%), and the lowest was among those aged 25-34 years (79%). Among the current smokers who reported visiting a healthcare provider in the preceding 12 months, 54% said that they were advised to reduce or quit smoking. Rates of advice to reduce or quit smoking were lowest among smokers aged 15-19 years (36%) and increased by age group (Table 1) .
Regarding types of health-care providers, 73% of current smokers reported visiting a physician in the preceding 12 months, whereas a smaller proportion reported visiting a dentist or dental hygienist (60%) or a pharmacist (38%) ( Table 2) . A greater portion of female smokers visited a physician (85%), dentist or dental hygienist (64%), or a pharmacist (44%) compared with male smokers (65%, 57%, and 33%, respectively). The highest rate of visiting a physician was among respondents aged >45 years (81%), visiting a dentist or dental hygienist was highest among those aged 15-19 years (71%), and visiting a pharmacist was highest among those aged >45 years (42%) ( Table 2 ).
Among the current smokers who reported visiting a physician in the preceding 12 months, approximately half (51%) said that they were advised to reduce or quit smoking. Rates of advice to reduce or quit smoking by a physician were lowest among the youngest smokers (i.e., aged 15-19 years) (38%) and increased by age group ( Table 2 ). The prevalence of being advised to reduce or quit smoking by a physician among young adult (aged 20-24 years) males and females was significantly different: 33% among males and 50% among females. Approximately 36% of respondents were advised to reduce or quit smoking by dentists or dental hygienists, whereas 16% of respondents received this advice from pharmacists. Overall, respondents reported a greater prevalence of pharmacists providing information on smoking-cessation aids (84%) compared with the other two categories of health-care providers (physician, 57%, and dentist or dental hygienist, 31%). Editorial Note: Although 88% of current smokers in Canada reported visiting a health-care provider in the preceding 12 months, only half of these smokers reported being advised to reduce or quit smoking. Health-care providers are in a unique position to offer smoking-cessation advice and provide information on smoking-cessation aids to their patients; however, the results of this analysis indicate that many of these opportunities are being missed.
In 2001, several Canadian health associations, including the Canadian Medical Association, Canadian Dental Association, and Canadian Pharmacists Association, prepared a joint statement outlining the role of the health-care provider in smoking cessation (4) . The statement focused on smoking cessation as part of a comprehensive strategy, specifically on the role of health-care providers in helping Canadians to stop smoking. The strategy highlighted the need for a collaborative, multidisciplinary approach to smoking cessation, requiring members to be prepared to discuss counseling, pharmacotherapy, ongoing support mechanisms, and relapse-prevention strategies with patients.
Although the need for smoking-cessation counseling has been recognized, barriers exist among health-care providers, including a need for additional training regarding smoking-cessation counseling, lack of time, low priority for tobacco-related matters, and a perceived lack of interest in * Determined by response to the question: "At the present time, do you smoke every day, occasionally, or not at all?" Respondents who answered "every day" or "occasionally" were classified as current smokers. † "In the past 12 months, did you see a doctor?" "In the past 12 months, did you see a dentist or dental hygienist?" "In the past 12 months, did you talk with a pharmacist?" § "Did the doctor advise you to reduce or quit smoking?" "Did the dentist or dental hygienist advise you to reduce or quit smoking?" "Did the pharmacist advise you to reduce or quit smoking?" ¶ "Did the doctor provide you with information on quit-smoking aids such as the patch, a product like Zyban, or counseling programs?" "Did the dentist or dental hygienist provide you with information on quit-smoking aids such as the patch, a product like Zyban, or counseling programs?" "Did the pharmacist provide you with information on quit smoking aids such as the patch, a product like Zyban, or counseling programs?" * Respondents were asked in separate questions whether they had visited a physician, dentist or dental hygienist, and pharmacist; responses were combined to derive the overall health-care provider variable. † Determined by response to the question: "At the present time, do you smoke every day, occasionally, or not at all?" Respondents who answered "every day" or "occasionally" were classified as current smokers. § Respondents who said they had visited a health-care provider in the preceding 12 months were asked whether the provider gave advice to reduce or quit smoking. ¶ Respondents who said they were advised to reduce or quit were asked if the health-care provider provided them with information on smoking-cessation aids such as nicotine patches, a product such as Zyban ® , or counseling services. ** Confidence interval.
quitting among patients (5, 6) . Certain clinicians simply might not know how to identify smokers quickly or know which treatments are effective and how these treatments can be provided (7) . Health-care-provider associations need to develop innovative approaches to support and motivate health-care providers to counsel patients who smoke (8) .
The medical, dental, and pharmacist associations in Canada endorse the need to educate members regarding their role in smoking cessation, provide members with current training and tools that will motivate and assist them in their roles as counselors and referral agents, and increase public awareness that health-care providers can offer support and resources to help persons stop smoking (4). Continuing education programs have been shown to substantially change the way health-care providers counsel smokers, resulting in higher quit rates (3). In addition, evidence-based studies have documented that health-careprovider advice alone can increase smoking-cessation rates from approximately 5% to 10%, and following up with patients who are trying to quit can double smoking-cessation rates (2, 3, 9) . Even brief interventions by healthcare providers can help adult smokers to quit (10) . In addition, use of smokingcessation drugs has been documented to increase the cessation rate for many patients (2) .
Despite missed opportunities in smoking-cessation consultation among healthcare providers, progress has been made in decreasing smoking prevalence overall in Canada. The findings in this report are subject to at least five limitations. First, CTUMS does not sample households without landline telephones. Second, the survey methodology did not determine the frequency, timing, and nature of respondent visits to health-care providers or healthcare-provider advice to reduce or quit smoking or offers of information on smoking-cessation aids. The variation in results by age might be explained, in part, by the number of visits to health-care providers by respondents during the preceding 12 months because the frequency of visits increases with age. In addition, the survey did not determine whether the respondents told their health-care providers that they smoked, which would affect the prevalence of providers offering advice. For example, pharmacists might have been less likely to ask patients whether they were smokers and might therefore have had a lower prevalence of giving cessation advice. Likewise, the type of encounter (e.g., emergency treatment versus routine or preventive care) would affect the likelihood that a provider would ask about smoking status and offer advice about smoking. The higher prevalence of advice to quit or reduce smoking among females aged 20-24 years compared with males of the same age might be a result of the nature of the visit, which was not assessed; for example, more females might have been * Respondents were asked in separate questions whether they had visited a physician, dentist or dental hygienist, and pharmacist. † Determined by response to the question: "At the present time, do you smoke every day, occasionally, or not at all?" Respondents who answered "every day" or "occasionally" were classified as current smokers. § Respondents who said they had visited a physician, dentist or dental hygienist, or pharmacist in the preceding 12 months were asked whether that provider gave advice to reduce or quit smoking. ¶ Respondents who said they were advised to reduce or quit were asked if that physician, dentist or dental hygienist, or pharmacist provided them with information on smokingcessation aids such as nicotine patches, a product such as Zyban ® , or counseling services. ** Confidence interval. † † Data are unreliable because of high sampling variability.
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advised to reduce or quit as they entered their childbearing and rearing years because of 1) the health effects of smoking during pregnancy and on children and 2) the contraindications of certain forms of birth control (i.e., pills or patches). Third, information on visits with health-care providers is self-reported and might be influenced by socialdesirability bias or recall bias. Fourth, although CTUMS describes the association between smoking behaviors and selected variables, conclusions regarding causation cannot be drawn from CTUMS cross-sectional data. Finally, the presented estimates of health-care-provider provision of smoking cessation advice to reduce or quit smoking and the provision of information on cessation aids might be an underestimate because the survey questions were only asked of current smokers. No information was collected from persons who had recently quit smoking but who might also have visited health-care providers and received cessation advice and information on cessation aids. A smoker's chance of quitting increases after receiving smoking-cessation information and support from various health-care providers in different disciplines (2,10). Although certain health-care providers have included smoking-cessation activities in their practices, the results indicate that either many health professionals are missing this opportunity to provide smoking-cessation advice or that smokers are not seeking this advice from their health-care providers. Practice guidelines to identify smokers and encourage cessation could help increase the number of smokers who receive smoking-cessation counseling from their health-care providers. 
Notice to Readers

Satellite Broadcast and Webcast: Immunization Update 2007
CDC and the Public Health Training Network will present a satellite broadcast and webcast, Immunization Update 2007, on August 9, 2007. The 2½-hour broadcast will occur live during 9:00-11:30 a.m. EST and will be rebroadcast the same day during 12:00-2:30 p.m. EST. Both broadcasts will feature a live question-and-answer session in which participants nationwide can interact with the course instructors via a toll-free telephone number. Anticipated topics include influenza, rotavirus, varicella, and zoster vaccines and other emerging vaccine topics. Continuing education (CE) credits will be provided. Additional information about the program is available at http:/ /www2a.cdc.gov/phtn/immup-2007.
Information for site administrators about establishing and registering a viewing location is available at http:// www.cdc.gov/phtnonline. This website also provides information for individual participants who would like to register to view the satellite broadcast from a specific location or for those seeking CE credit.
No registration is necessary to view the webcasts via the Internet; the link to the live webcast is available at http:// www2a.cdc.gov/phtn/webcast/immup-2007. The webcast will be accessible via the Internet connection until September 11, 2007. The program will become available as a self-study DVD and Internet-based program in September 2007.
Notice to Readers
Revised International Health Regulations Effective for the United States
On July 18, 2007, the revised International Health Regulations (IHRs) entered into effect for the United States. IHRs are an international legal framework designed to help contain or prevent serious risks to public health while discouraging unnecessary or excessive restrictions on travel or trade. In 2005, approximately one fourth of the 2.4 million hospitalizations for children aged <15 years were for respiratory diseases, the largest category of hospitalization diagnoses in this age group. Of these, 31% were for pneumonia, 25% for asthma, 25% for acute bronchitis and bronchiolitis, and 19% for other respiratory diseases, including croup and chronic disease of tonsils and adenoids. 1  23  67  484  602  131  111  259  2,966  2,945  -3  19  95  86  Connecticut  -5  25  129  139  60  43  204  1,105  1,194  -0  6  29  24  Maine§   -4  14  68  43  3  2  8  63  69  -0  4  7  7  Massachusetts  -9  26  194  285  53  49  96  1,450  1,276  -2  5  48  40  New Hampshire  -0  3  5  14  3  2  8  87  120  -0  2  6  6  Rhode Island§   -0  17  28  45  10  9  19  231  251  -0  10  4  2  Vermont§   1  3  12  60  76  2  1  5  30  35  -0  1 14  12  92  359  680  13  10  106  262  270  4  1  11  61  50  Alaska  -0  1  2  1  -0  3  4  2  -0  1  --California  12  10  40  317  648  9  7  31  195  219  3  1  11  47  50  Hawaii  -0  1  3  8  -0  1  -5  -0  1  1  -Oregon§   -1  3  16  23  -1  5  36  44  -0  1  3  -Washington  2  0  52  21  -4  0  74  27  -1  0  2 10 - -0  0  ---0  2  -1  -0  2  7  6  Louisiana  -0  1  2  --0  2  12  3  -0  4  15  28  Oklahoma  -0  0  --1  0  3  4  3  -0  4  14  8  Texas§   -1  5  28  7  -1  25  21  36  -0  11  21  25   Mountain  -1  3  12  7  -1  6  30  34  1  1  5  47  42  Arizona  -0  1  -4  -0  3  5  12  -0  3  13  11  Colorado  -0  1  1  --0  2  11  10  -0  2  15  14  Idaho§   -0  2 Pacific  10  2  16  71  33  3  3  45  71  105  1  4  48  144  168  Alaska  -0  1  2  1  -0  4  2  14  -0  1  1  2  California  10  2  8  68  30  2  2  6  46  79  1  3  10  104  133  Hawaii  N  0  0  N  N  -0  1  2  5  -0  1  2  4  Oregon§   -0  1  1  2  -0  3  12  7  -0  3  23  29  Washington  -0  8  --1  0  43  9  --0  43 14 - 6  19  163  491  579  47  40  65  1,067  1,248  36  14  67  374  506  Delaware  -0  2  6  3  -0  0  ---0  2  7  12  District of Columbia  -0  2  2  3  -0  0  ---0  1  1  -Florida  5  4  18  124  117  -0  27  71  176  -0  4  10  8  Georgia  -1  5  14  53  16  4  9  97  138  -0  5  10  21  Maryland†   -2  8  63  84  -6  17  145  228  -1  7  24  39  North Carolina  -3  112  180  105  8  11  21  270  240  33  6  61  246  383  South Carolina†   -2  11  44  83  -3  11  46  80  -1  6  25  15  Virginia†   -2  17  48  109  23  12  31  400  333  3  2  12  49  27  West Virginia  1  0  19  10  22  -1  8  38  53  -0  2  2  1 E.S. Central  -5  24  104  165  -3  11  62  139  2  6  27  113  124  Alabama†   -1  18  31  34  -0  8  -47  2  1  9  29  30  Kentucky  -0  5  2  32  -0  4  10  7  -0  1  3  1  Mississippi  -0  10  17  19  -0  0  -4  -0  1  2  2  Tennessee†   -3  9  54  80  -2  8  52  81  -4  22 79 91 17  18  226  355  382  1  8  35  60  481  18  1  168  54  31  Arkansas†   17  2  17  92  40  1  0  5  15  19  7  0  53  14  21  Louisiana  -0  2  6  17  -0  1  -2  -0  1  --Oklahoma  -0  36  2  10  -0  22  45  44  11  0  108  32  5  Texas†   -15  174  255  315  -0  34  -416  -0  7  8  5   Mountain  11  27  61  614  1,660  -3  28  69  86  -0  4  15  16  Arizona  -6  17  150  349  -2  10  50  66  -0  2  -5  Colorado  3  6  17  166  531  -0  0  ---0 507  807  2,338  17,486  18,321  52  75  336  1,458  1,430  236  311  1,287  7,007  5,646   New England  3  34  199  927  1,254  -3  25  87  143  -4  16  97  167  Connecticut  -0  185  185  503  -0  20  20  75  -0  13  13  67  Maine§   -2  14  53  42  -1  8  17  6  -0  5  12  2  Massachusetts  -22  60  542  550  -1  6  37  45  -3  11  63  86  New Hampshire  -3  15  55  97  -0  3  5  11  -0  2  3  4  Rhode Island§   -1  20  51  41  -0  2  2  2  -0  3 7  25  84  416  611  Hawaii  1  5  16  121  116  -0  3  8  6  -1  3  16  24  Oregon§   2  7  17  162  210  -1  9  20  32  -1  6  35  73  Washington  11  1  625  298  2  1  0  162  38  -3  0  170 -0  0  ---0  0  --10  38  57  972  1,103  Alaska  -0  0  ---0  0  ---0  2  5  5  California  N  0  0  N  N  -0  0  --1  36  54  888  968  Hawaii  -0  0  ---0  0  ---0  1  5 
SOURCE:
- - - 1 1 - 1 1 SARS-CoV §, § § § - - - - - - 8 N Smallpox § - - - - - - - - StreptococcalN 0 0 N N - 0 0 - - American Samoa U 0 32 U U U 0 0 U U U 0 0 U U C.N.M.I. U - - U U U - - U U U - - U U Guam - 16 18 - 491 - 0 0 - - - 0 0 - - Puerto Rico 124 122 233 3,905 2,630 N 0 0 N N N 0 0 N N U.S. Virgin Islands U 3 7 U U U 0 0 U U U 0 0 U U
New England
American Samoa U 0 0 U U U 0 4 U U U 0 0 U U C.N.M.I. U - - U U U - - U U U - - U U Guam - 0 0 - - - 1 6 - 52 - 0 0 - 1- 0 1 1 1 - 0 1 - - - 0 1 3 - PacificAmerican Samoa U 0 0 U U U 0 0 U U U 0 0 U U C.N.M.I. U - - U U U - - U U U - - U U Guam - 0 0 - - - 0 0 - - - 0 0 - - Puerto4 - - 0 1 - - - 0 1 3 1 Montana § - 0 1 1 - - 0 1 2 1 - 0 1 1 3 Nevada § - 0 2 5 1 - 0 1 2 1 - 0 1 3 4 New Mexico § - 0 1 - 2 - 0 1 1 3 - 0 1 2 2 Utah - 0 1 1 - - 0 3 9 7 1 0 2 8 5 Wyoming § - 0 1 - - - 0 0 - - - 0 2 2 2American Samoa U 0 0 U U U 0 0 U U U 0 0 - - C.N.M.I. U - - U U U - - U U U - - - - Guam - 0 0 - - - 0 0 - - - 0 0 - - Puerto Rico N 0 0 N N - 0 1 1 - 1 0 1 6 4 U.S. Virgin Islands U 0 0 U U U 0 0 U U U 0 0 - -
S. Atlantic
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- - 0 0 - - N 0 0 N N American Samoa U 0 0 U U U 0 0 U U U 0 0 U U C.N.M.I. U - - U U U - - U U U - - U U Guam - 1 7 - 20 - 0 0 - - N 0 0 N N Puerto Rico - 0 1 - - - 1 5 26 56 N 0 0 N N U.S. Virgin Islands U 0 0 U U U 0 0 U U U 0 0 U U
United States
